covid-19 |
69 |
sars-cov-2 |
45 |
primary care |
40 |
covid-19 vaccine |
39 |
mortality |
36 |
cardiovascular diseases |
31 |
type 2 diabetes mellitus |
31 |
bnt162b2 |
29 |
coronavac |
29 |
vaccine safety |
29 |
covid-19 vaccines |
27 |
complications |
26 |
hypertension |
24 |
type 2 diabetes |
24 |
diabetes mellitus |
22 |
chinese |
19 |
epidemiology |
18 |
inactivated vaccine |
18 |
primary health care |
18 |
self-controlled case series |
18 |
cardiovascular disease |
17 |
diabetes |
17 |
long covid |
17 |
risk stratification |
17 |
health-related quality of life |
16 |
nomogram |
16 |
public health |
16 |
stroke |
16 |
colorectal cancer |
15 |
responsiveness |
15 |
vaccine effectiveness |
15 |
coronavirus infection |
14 |
health outcomes |
14 |
heart failure |
14 |
hemoglobin a1c |
14 |
antivirals |
13 |
blood pressure |
13 |
cardiovascular complications |
13 |
cardiovascular magnetic resonance |
13 |
mental health |
13 |
microvascular complications |
13 |
quality of care |
13 |
quality of life |
13 |
adverse events |
12 |
chronic diseases |
12 |
chronic kidney disease |
12 |
cohort study |
12 |
health services |
12 |
innate immunity |
12 |
non-communicable diseases |
12 |
tuberculosis |
12 |
chronic liver disease |
11 |
cirrhosis |
11 |
general practice |
11 |
graves disease |
11 |
health economics |
11 |
hepatocellular carcinoma |
11 |
hong kong |
11 |
hospitalisation |
11 |
hyperthyroidism |
11 |
hypothyroidism |
11 |
omicron |
11 |
post-covid-19 syndrome |
11 |
prediction model |
11 |
preventive medicine |
11 |
sars-cov-2 infection |
11 |
screening |
11 |
sf-12 |
11 |
thyroid dysfunction |
11 |
variability |
11 |
atrial fibrillation |
10 |
autoimmune disorders |
10 |
bidirectional relationship |
10 |
child health |
10 |
delirium |
10 |
dementia |
10 |
effectiveness |
10 |
incident cvd |
10 |
ischemic stroke |
10 |
low-income families |
10 |
major adverse cardiovascular events |
10 |
metformin |
10 |
parental stress |
10 |
pasc |
10 |
post-acute sequelae of sars-cov-2 |
10 |
post-covid cvd |
10 |
prognosis |
10 |
sex difference |
10 |
adverse events of special interest (aesi) |
9 |
cancer |
9 |
chest x-ray |
9 |
end stage renal disease |
9 |
infection |
9 |
molnupiravir |
9 |
nirmatrelvir-ritonavir |
9 |
pediatrics |
9 |
pharmacovigilance |
9 |
safety |
9 |
stress |
9 |
vaccine |
9 |
viral disease |
9 |
waning vaccine effectiveness |
9 |
white cell count |
9 |
4d flow |
8 |
adverse events of special interest |
8 |
all-cause mortality |
8 |
ckd |
8 |
cohort studies |
8 |
database research diabetes complications population study primary care type 2 diabetes |
8 |
direct flow |
8 |
ehr |
8 |
emulated trial |
8 |
hfpef |
8 |
indirect effect |
8 |
intraventricular flow |
8 |
machine learning |
8 |
management programme |
8 |
meta-analysis |
8 |
mrna vaccine |
8 |
myocarditis |
8 |
odds ratio |
8 |
pediatric population |
8 |
pericarditis |
8 |
recurrent cardiovascular events |
8 |
residual volume |
8 |
risk |
8 |
risk assessment |
8 |
risk prediction score |
8 |
systematic review |
8 |
anchor |
7 |
anxiety |
7 |
aspirin |
7 |
cardiovascular disease risk |
7 |
depression |
7 |
dialysis patients |
7 |
fact-c |
7 |
general diabetes |
7 |
geriatrics |
7 |
glycated haemoglobin |
7 |
health-related quality of life (hrqol) |
7 |
lower urinary tract symptoms |
7 |
management |
7 |
mental disorders |
7 |
multidisciplinary |
7 |
myocardial infarction |
7 |
nursing |
7 |
peritoneal dialysis |
7 |
quality in health care |
7 |
renal replacement therapy |
7 |
short form-12 health survey version 2 (sf-12v2) |
7 |
vaccination |
7 |
visit‐to‐visit variability |
7 |
asymptomatic |
6 |
china |
6 |
cohort |
6 |
continuity of care |
6 |
cost-effectiveness |
6 |
cvd |
6 |
follow - up care |
6 |
gastroenterology |
6 |
gastrointestinal tumours |
6 |
glycemic control |
6 |
haemoglobin a1c |
6 |
hdl‐c |
6 |
high cardiovascular risk |
6 |
intercalation enrichment year |
6 |
ldl‐c |
6 |
learning experience |
6 |
life expectancy |
6 |
lipids |
6 |
lipids variability |
6 |
medical sciences |
6 |
mixed-method study |
6 |
mortality risk |
6 |
non-steroidal anti-inflammatory drugs |
6 |
nsaids |
6 |
pharmacoepidemiology |
6 |
physician encounters |
6 |
prediction |
6 |
prevention |
6 |
real-world evidence |
6 |
risk algorithm |
6 |
risk factors |
6 |
risk prediction |
6 |
stress cardiac magnetic resonance |
6 |
studiesmortality |
6 |
type 2 diabetes mellitus (t2dm) |
6 |
undergraduate medicine curriculum |
6 |
undiagnosed diabetes |
6 |
validation |
6 |
volume–outcome |
6 |
volume–quality |
6 |
adenosine triphosphate |
5 |
antibiotics |
5 |
chinese medicine;multi-centre |
5 |
clinical parameters |
5 |
community centre |
5 |
competing risks |
5 |
continuity of patient care |
5 |
coronary artery disease |
5 |
corticosteroids |
5 |
costing analysis |
5 |
database research |
5 |
dating apps |
5 |
dialysis |
5 |
enalapril |
5 |
endocrinology |
5 |
end‐ |
5 |
end‐stage renal disease |
5 |
fact-p |
5 |
haemodialysis |
5 |
health policy |
5 |
health related quality of life |
5 |
healthcare costs |
5 |
healthcare expenditure |
5 |
hospital |
5 |
hypertension (ht) |
5 |
instrument |
5 |
interferons |
5 |
mediation |
5 |
medical education & training |
5 |
medication safety |
5 |
men who have sex with men |
5 |
multi-disciplinary |
5 |
multidisciplinary-risk-assessment-and-management-programme |
5 |
multimorbidity |
5 |
nocturia |
5 |
nocturnal home haemodialysis |
5 |
observational study |
5 |
orphan drug designation |
5 |
patient-reported outcomes |
5 |
patient‐reported outcome |
5 |
pharmacoepidemiolgy |
5 |
physiology |
5 |
population-based cohort |
5 |
postmarketing surveillance |
5 |
predictors |
5 |
prostate cancer |
5 |
recurrence |
5 |
risk prediction model |
5 |
risky sexual behaviours |
5 |
risk–benefit trade-off |
5 |
sacubitril/valsartan |
5 |
self-management |
5 |
sexual health |
5 |
sf-12v2 |
5 |
sleep quality |
5 |
stage renal disease |
5 |
structured education |
5 |
survival |
5 |
temporal trend |
5 |
trends |
5 |
young age of onset |
5 |
accident and emergency department attendances |
4 |
active transport |
4 |
acute wound |
4 |
asians |
4 |
assessment |
4 |
bmi |
4 |
bodily pain |
4 |
chronic wound |
4 |
colonoscopy |
4 |
conservative treatment |
4 |
coronary heart disease |
4 |
depressive disorders |
4 |
family medicine |
4 |
family practice |
4 |
fecal occult blood testing |
4 |
genetic susceptibility |
4 |
good hrqol |
4 |
hba1c |
4 |
health seeking |
4 |
health services research |
4 |
hospital admissions |
4 |
hrqol data |
4 |
hrqol outcome |
4 |
hrqol score |
4 |
incidence |
4 |
incontinence |
4 |
instrument development |
4 |
macrovascular disease |
4 |
mass screening |
4 |
microvascular disease |
4 |
morbidity |
4 |
morbidity survey |
4 |
multidisciplinary intervention |
4 |
nurse practitioners urology |
4 |
outcomes research methods |
4 |
outpatient clinics |
4 |
patient-reported outcome |
4 |
practice-based research |
4 |
predictor |
4 |
prevalence |
4 |
psychometric testing |
4 |
quality of life (qol) |
4 |
ramp-dm |
4 |
risk assessment and management |
4 |
risk factor |
4 |
risk management |
4 |
substance use disorders |
4 |
trajectory |
4 |
type 2 diabetes, structured education |
4 |
uk biobank |
4 |
urology |
4 |
wound assessment |
4 |
action research |
3 |
addqol-19 |
3 |
audit |
3 |
bother |
3 |
cardiovascular events |
3 |
delivery of care |
3 |
depressive disorder |
3 |
diabetes care |
3 |
eortc qlq-c30 |
3 |
estimated glomerular filtration rate (egfr) |
3 |
health personnel |
3 |
health service |
3 |
health status |
3 |
hepatitis c virus (hcv) |
3 |
latent class analysis |
3 |
linkage-to-care |
3 |
mapping |
3 |
novel predictor |
3 |
patient acceptance of health care |
3 |
population-based |
3 |
preference-based |
3 |
preference-based scores |
3 |
sf-6d |
3 |
shared care |
3 |
statin |
3 |
structure of care |
3 |
testing |
3 |
tree analysis |
3 |
urine albumin-to-creatinine ratio (uacr) |
3 |
validity |
3 |
adult |
2 |
anticipated regret |
2 |
attitude |
2 |
consultation |
2 |
coronavirus disease 2019 |
2 |
cross-sectional study |
2 |
family doctors |
2 |
impaired fasting glucose |
2 |
intention |
2 |
internet |
2 |
non-insulin-dependent diabetes - complications |
2 |
non-insulin-dependent diabetes - mortality |
2 |
pandemic |
2 |
preparedness |
2 |
self-efficacy |
2 |
sleep |
2 |
young adult |
2 |
atherosclerosis |
1 |
carotid intima‐media thickness |
1 |
first-ever stroke |
1 |
lean body mass |
1 |